AXGN
AxoGen, Inc. · Healthcare · Medical - Devices
Momentum inputs (comparable managers):
holder breadth -18.8% ·
share flow -3.2% ·
net new positions -20.0%
— formula
Broad distribution — falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 97 | +13 | 31.59M | $1.46B | +13 | −1 |
| Q1 2026 | 88 | +4 | 26.93M | $890.85M | +13 | −9 |
| Q4 2025 | 84 | +1 | 23.54M | $770.31M | +1 | — |
| Q3 2025 | 15 | 0 | 12.88M | $229.79M | +1 | −2 |
| Q2 2025 | 13 | -3 | 10.16M | $110.24M | — | −3 |
| Q1 2025 | 13 | +1 | 4.00M | $74.03M | +1 | — |
| Q4 2024 | 12 | +1 | 2.94M | $48.52M | +2 | −1 |
| Q3 2024 | 10 | +4 | 2.95M | $41.31M | +4 | — |
| Q2 2024 | 6 | — | 2.53M | $18.31M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 3.50M | — | $37.98M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | BlackRock ✦ (passive) | 3.50M | — | $37.98M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | BlackRock ✦ (passive) | 3.50M | — | $37.98M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | BlackRock ✦ (passive) | 3.50M | — | $37.98M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | BlackRock ✦ (passive) | 3.50M | — | $37.98M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | BlackRock ✦ (passive) | 3.50M | — | $37.98M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | BlackRock ✦ (passive) | 3.50M | — | $37.98M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | BlackRock ✦ (passive) | 3.50M | — | $37.98M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | BlackRock ✦ (passive) | 3.50M | — | $37.98M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | BlackRock ✦ (passive) | 3.50M | — | $37.98M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | BlackRock ✦ (passive) | 3.50M | — | $37.98M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | The Vanguard Group ✦ (passive) | 2.73M | — | $29.62M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | The Vanguard Group ✦ (passive) | 2.73M | — | $29.62M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | The Vanguard Group ✦ (passive) | 2.73M | — | $29.62M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | The Vanguard Group ✦ (passive) | 2.73M | — | $29.62M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | The Vanguard Group ✦ (passive) | 2.73M | — | $29.62M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | State Street Global Advisors ✦ (passive) | 1.12M | +10.7% | $12.18M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 18 | Geode Capital Management ✦ (passive) | 1.06M | +3.3% | $11.51M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 19 | Geode Capital Management ✦ (passive) | 1.06M | +3.3% | $11.51M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 20 | Marshall Wace ✦ | 641.43K | -4.0% | $6.96M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 21 | Marshall Wace ✦ | 641.43K | -4.0% | $6.96M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 22 | D. E. Shaw & Co. ✦ | 448.43K | -20.3% | $4.87M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 23 | Fidelity (FMR) ✦ | 268.87K | — | $2.92M | 0.0% | n/c | 1 | SEC ↗ |
| 24 | Fidelity (FMR) ✦ | 268.87K | — | $2.92M | 0.0% | n/c | 1 | SEC ↗ |
| 25 | Renaissance Technologies ✦ | 142.00K | +129.0% | $1.54M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 26 | Millennium Management ✦ | 104.39K | +805.4% | $1.13M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 27 | Norges Bank ✦ (passive) | 61.10K | -20.6% | $662,935 | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 28 | T. Rowe Price ✦ | 39.40K | +9.4% | $428,000 | 0.0% | ▲ Add | 5 | SEC ↗ |
| 29 | Arrowstreet Capital ✦ | 29.12K | -70.1% | $315,974 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 30 | Two Sigma Investments ✦ | 10.96K | -93.3% | $118,916 | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Citadel Advisors | $3.78M | was 0.0% |
| Point72 Asset Management | $982,350 | was 0.0% |
| AQR Capital Management | $442,465 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 219 holders, 49.68M shares, $1.61B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 13.35K sh · $646,592
Officer · 67.50K sh · $3.20M
Director · 14.15K sh · $640,967
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology